Revelation Biosciences, Inc. (REVB)

Revelation Biosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	12.71	6.5	11.99	5.25	1.27	4.49
Cash & Short-Term Investments	12.71	6.5	11.99	5.25	1.27	4.49
Cash Growth	94.29%	-45.80%	128.28%	312.09%	-71.63%	-
Prepaid Expenses	0.12	0.07	0.08	0.07	0.64	0.13
Other Current Assets	-	-	0.07	0.09	-	-
Total Current Assets	12.83	6.57	12.15	5.41	1.91	4.62
Property, Plant & Equipment	0.02	0.06	0.07	0.09	0.13	-
Total Assets	12.86	6.62	12.21	5.5	2.04	4.62
Accounts Payable	1.03	0.78	1.36	0.55	0.6	0.87
Accrued Expenses	0.82	1.13	1.15	0.99	1.53	0.34
Current Portion of Leases	-	-	-	-	0.02	-
Other Current Liabilities	0	0	3.05	2.91	-	-
Total Current Liabilities	1.85	1.91	5.56	4.45	2.14	1.21
Total Liabilities	1.85	1.91	5.56	4.45	2.14	1.21
Common Stock	0	0	0	0	0	0
Additional Paid-In Capital	57.91	45.21	32.11	26.4	14.42	5.54
Retained Earnings	-46.91	-40.51	-25.47	-25.35	-14.52	-2.53
Total Common Equity	11	4.71	6.65	1.05	-0.1	3.01
Shareholders' Equity	11	4.71	6.65	1.05	-0.1	3.41
Total Liabilities & Equity	12.86	6.62	12.21	5.5	2.04	4.62
Total Debt	-	-	-	-	0.02	-
Net Cash (Debt)	12.71	6.5	11.99	5.25	1.26	4.49
Net Cash Growth	94.29%	-45.80%	128.28%	317.57%	-72.00%	-
Net Cash Per Share	12.99	113.68	-	-	-	-
Filing Date Shares Outstanding	5.92	0.3	0.03	-	-	-
Total Common Shares Outstanding	3.59	0.17	-	-	-	-
Working Capital	10.98	4.65	6.58	0.96	-0.23	3.41
Book Value Per Share	3.07	27.05	-	-	-	-
Tangible Book Value	11	4.71	6.65	1.05	-0.1	3.01
Tangible Book Value Per Share	3.07	27.05	-	-	-	-
Machinery	-	0.15	0.13	0.13	0.13	-

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q